Drug Profile
CB 002
Alternative Names: CB-002; GC enriched liposomal mitoxantrone - Ceronco Biosciences; Glucosylceramide enriched liposomal mitoxantrone - Ceronco Biosciences; Mitoxantrone liposomal - Ceronco BiosciencesLatest Information Update: 28 Nov 2020
Price :
$50
*
At a glance
- Originator Ceronco Biosciences
- Class Amines; Anthraquinones; Antineoplastics; Small molecules
- Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Pancreatic cancer; Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 28 Nov 2020 No recent reports of development identified for preclinical development in Pancreatic-cancer in Netherlands
- 28 Nov 2020 No recent reports of development identified for preclinical development in Precursor-cell-lymphoblastic-leukaemia-lymphoma(In adolescents, In children, In infants) in Netherlands
- 26 Oct 2016 Preclinical trials in Acute lymphoblastic leukaemia (In children, In infants, In adolescents) in Netherlands (unspecified route)